Logistics services for high-quality blood plasma products
Movianto takes over central Europe logistics for
CSL Behring
Stuttgart, Germany, 7 May 2008
Movianto has set up a central European distribution centre
for the logistics and distribution of CSL Behring's pharmaceutical
products. As one of the leading providers of logistics and
distribution services to the pharmaceutical, biotechnology
and healthcare industry in Europe, Movianto ensures the
storage and Europe-wide distribution of the manufacturer's
blood plasma products and guarantees that the cool chain
for this highly-sensitive products is not interrupted at
any point.
In addition to its location and the quality of the service
it provides, the fact that Movianto's European distribution
centre guarantees deliveries within the agreed times was
a decisive factor in CSL Behring's choice. CSL Behring was
also won over by the central IT platform Movianto Prince:
It provides a high level of transparency across the entire
supply chain, as relevant data like stock levels, for example,
can be called up in real time via standard interfaces and
reports.
"Further to this our reasons for choosing Movianto
were" commented Uli Kiefer, Senior Director Global
Logistics at CSL Behring, "that during the whole process
of warehousing and distribution all product requirements,
for example, permanent temperature control, are met."
Movianto is responsible for all tasks across the supply
chain for CSL Behring: from goods entry to cool storage
via pick & pack and dispatch to cool chain transportation
to pharmacies and hospitals in Austria, Denmark and Germany.
Additionally Movianto will supply other warehouses throughout
Europe.
In order to meet the constantly growing demand for cool
storage, Movianto in Germany has expanded the warehouse
in Neunkirchen by 2,000 cool pallet storage units thus guaranteeing
that the cold chain is not interrupted at any time. In the
warehouse itself a permanent temperature monitoring guarantees
the constant cooling from 2 to 8ºC.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics
industry. Passionate about improving the quality of patients'
lives, CSL Behring manufactures and markets a range of safe
and effective plasma-derived and recombinant products and
related services. The company's therapies are used in the
treatment of immune deficiency disorders, hemophilia, other
bleeding disorders and inherited emphysema. Other products
are used for the prevention of hemolytic diseases in the
newborn, in cardiac surgery, organ transplantation and in
the treatment of burns. The company also operates one of
the world's largest plasma collection networks, ZLB Plasma.
CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical
company with headquarters in Melbourne, Australia. For more
information, please visit
 www.cslbehring.com.
Download
press release as PDF
|
